FDA Advisory Panel Cautiously Endorses Abbott Xience V Drug-Eluting Stent
This article was originally published in The Gray Sheet
Executive Summary
FDA's Circulatory System Devices panel overwhelmingly endorsed PMA approval of Abbott's Xience V everolimus-eluting, despite reservations about its long-term safety
You may also be interested in...
SPIRIT II Yields Mixed Results For Xience Drug-Eluting Stent
Boston Scientific and Abbott are emphasizing the safety and clinical effectiveness of the Xience V everolimus-eluting stent shown in the SPIRIT II trial while downplaying the disappointing angiographic results
SPIRIT II Yields Mixed Results For Xience Drug-Eluting Stent
Boston Scientific and Abbott are emphasizing the safety and clinical effectiveness of the Xience V everolimus-eluting stent shown in the SPIRIT II trial while downplaying the disappointing angiographic results
Boston Scientific Marks Progress On Regulatory, Restructuring Efforts
Boston Scientific expects FDA to lift restrictions stemming from a two-year-old corporate warning letter by mid-year following the agency's recent commencement of manufacturing site inspections, the company says